Literature DB >> 21907926

Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL.

Raghuveer Singh Mali1, Baskar Ramdas, Peilin Ma, Jianjian Shi, Veerendra Munugalavadla, Emily Sims, Lei Wei, Sasidhar Vemula, Sarah C Nabinger, Charles B Goodwin, Rebecca J Chan, Fabiola Traina, Valeria Visconte, Ramon V Tiu, Timothy A Lewis, Andrew M Stern, Qiang Wen, John D Crispino, H Scott Boswell, Reuben Kapur.   

Abstract

We show constitutive activation of Rho kinase (ROCK) in cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL, which is dependent on PI3K and Rho GTPase. Genetic or pharmacologic inhibition of ROCK in oncogene-bearing cells impaired their growth as well as the growth of acute myeloid leukemia patient-derived blasts and prolonged the life span of mice bearing myeloproliferative disease. Downstream from ROCK, rapid dephosphorylation or loss of expression of myosin light chain resulted in enhanced apoptosis, reduced growth, and loss of actin polymerization in oncogene-bearing cells leading to significantly prolonged life span of leukemic mice. In summary we describe a pathway involving PI3K/Rho/ROCK/MLC that may contribute to myeloproliferative disease and/or acute myeloid leukemia in humans.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907926      PMCID: PMC3207244          DOI: 10.1016/j.ccr.2011.07.016

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  54 in total

Review 1.  Cellular mechanics as an indicator of cytoskeletal structure and function.

Authors:  E L Elson
Journal:  Annu Rev Biophys Biophys Chem       Date:  1988

2.  Establishment of an immature mast cell line from a patient with mast cell leukemia.

Authors:  J H Butterfield; D Weiler; G Dewald; G J Gleich
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

3.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

4.  Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients.

Authors:  M Baudard; J P Marie; M Cadiou; F Viguié; R Zittoun
Journal:  Br J Haematol       Date:  1994-01       Impact factor: 6.998

Review 5.  Signal transduction and regulation in smooth muscle.

Authors:  A P Somlyo; A V Somlyo
Journal:  Nature       Date:  1994-11-17       Impact factor: 49.962

6.  Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)

Authors:  K Kimura; M Ito; M Amano; K Chihara; Y Fukata; M Nakafuku; B Yamamori; J Feng; T Nakano; K Okawa; A Iwamatsu; K Kaibuchi
Journal:  Science       Date:  1996-07-12       Impact factor: 47.728

7.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Authors:  H Nagata; A S Worobec; C K Oh; B A Chowdhury; S Tannenbaum; Y Suzuki; D D Metcalfe
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

Review 8.  Myosin phosphorylation/dephosphorylation and regulation of airway smooth muscle contractility.

Authors:  P de Lanerolle; R J Paul
Journal:  Am J Physiol       Date:  1991-08

9.  A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells.

Authors:  X Piao; A Bernstein
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

10.  Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines.

Authors:  H Kitayama; Y Kanakura; T Furitsu; T Tsujimura; K Oritani; H Ikeda; H Sugahara; H Mitsui; Y Kanayama; Y Kitamura
Journal:  Blood       Date:  1995-02-01       Impact factor: 22.113

View more
  48 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 2.  Kinase signaling and targeted therapy for primary myelofibrosis.

Authors:  Qiong Yang; John D Crispino; Qiang Jeremy Wen
Journal:  Exp Hematol       Date:  2016-12-30       Impact factor: 3.084

3.  Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a Cbl/Cbl-b deficiency-driven murine model of myeloproliferative disorders.

Authors:  Basem M William; Wei An; Dan Feng; Scott Nadeau; Bhopal C Mohapatra; Matthew A Storck; Vimla Band; Hamid Band
Journal:  Hematology       Date:  2015-07-15       Impact factor: 2.269

4.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Baskar Ramdas; Raghuveer Singh Mali; Holly Martin; Michihiro Kobayashi; Sasidhar Vemula; Victor H Canela; Emily R Waskow; Valeria Visconte; Ramon V Tiu; Catherine C Smith; Neil Shah; Kevin D Bunting; H Scott Boswell; Yan Liu; Rebecca J Chan; Reuben Kapur
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

5.  Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.

Authors:  Raghuveer Singh Mali; Peilin Ma; Li-Fan Zeng; Holly Martin; Baskar Ramdas; Yantao He; Emily Sims; Sarah Nabinger; Joydeep Ghosh; Namit Sharma; Veerendra Munugalavadla; Anindya Chatterjee; Shuo Li; George Sandusky; Andrew W Craig; Kevin D Bunting; Gen-Sheng Feng; Rebecca J Chan; Zhong-Yin Zhang; Reuben Kapur
Journal:  Blood       Date:  2012-07-17       Impact factor: 22.113

6.  ROCK1 functions as a critical regulator of stress erythropoiesis and survival by regulating p53.

Authors:  Sasidhar Vemula; Jianjian Shi; Raghuveer Singh Mali; Peilin Ma; Yan Liu; Philip Hanneman; Karl R Koehler; Eri Hashino; Lei Wei; Reuben Kapur
Journal:  Blood       Date:  2012-08-13       Impact factor: 22.113

7.  p85β regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis.

Authors:  Subha Krishnan; Raghuveer Singh Mali; Baskar Ramdas; Emily Sims; Peilin Ma; Joydeep Ghosh; Veerendra Munugalavadla; Philip Hanneman; Joal D Beane; Reuben Kapur
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

Review 8.  Role of Rho kinases in abnormal and normal hematopoiesis.

Authors:  Raghuveer Singh Mali; Simryn Kapur; Reuben Kapur
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

9.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 10.  Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy.

Authors:  Nicola Rath; Michael F Olson
Journal:  EMBO Rep       Date:  2012-09-11       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.